Numerus

Executive Summary

Numerus is a UK-based biostatistics consultancy founded in 2017, specializing in providing expert statistical support for clinical development and market access. The company focuses on the design and analysis of randomized clinical trials, health technology assessment (HTA), and real-world evidence (RWE) generation. Its services are aimed at helping pharmaceutical, medical device, and diagnostic companies navigate regulatory and payer requirements. As a private consultancy, Numerus operates in a niche but critical segment of the drug development value chain, where demand for rigorous statistical analysis is growing due to regulatory complexity and the rise of personalized medicine. Despite its specialized expertise, Numerus faces competition from larger CROs and statistical firms. However, its focus on HTA and RWE positions it well for the increasing emphasis on real-world data in regulatory decisions. The company's growth is likely tied to its ability to secure repeat business and expand its client base. With no disclosed funding rounds or financials, the investment thesis hinges on the steady demand for biostatistics services and potential for scalable growth through strategic partnerships. Key risks include dependency on a limited number of clients and the challenge of differentiating in a crowded market.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a leading CRO or pharmaceutical company40% success
• Q2 2027Expansion of service offerings into new therapeutic areas (e.g., gene therapy)50% success
• TBDNew regulatory guidance emphasizing RWE that increases demand for HTA services70% success